Shan Dong Kexing Bioproducts Co.Ltd(688136) it was announced that the company received the notice of approval of drug supplementary application approved and issued by the State Food and drug administration. On the basis of the original approved indications and specifications, the company’s drug human erythropoietin injection added the indications of “treating anemia caused by chemotherapy for non bone marrow malignant tumors” and the specifications of 36000iu / 1ml / bottle. In the treatment of “anemia caused by chemotherapy for non bone marrow malignant tumors”, large-scale human erythropoietin products can significantly reduce the frequency of medication and improve the medication compliance of patients on the premise of equal curative effect.
© China Stock Market News